Compare ARK Genomic Revolution ETF (ARKG) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Xylem, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Xylem, Inc. trades at $120.88 (market cap $28.81B). The key difference: Xylem, Inc. pays a 1.42% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Xylem, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | XYL | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $152.95 |
52-Week Low | $23.09 | $106.34 |
Market Cap | — | $28.81B |
Enterprise Value | — | $30.07B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
XYL trades at $121.22, up 1.96% with a bullish technical outlook. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding expectations. Revenue grew to $9.04B in 2025, and net income margin improved to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. The company maintains a strong balance sheet with total assets of $16.49B and shareholder equity of $10.64B as of 2024.
XYL presents a favorable investment case with analyst consensus price target of $153.14, implying 26% upside. Strengths include steady revenue growth, expanding margins, and positive cash flow trends. Risks involve market volatility and execution challenges in scaling new partnerships. Institutional sentiment is mixed but leans bullish, supported by a 47.5% buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
